Transaction DateRecipientSharesTypePriceValue
12th October 2020Sanj K Patel150,700Exercise of derivative$1.59$239,613.00
12th October 2020Sanj K Patel99,330Open or private sale$21.02$2,087,916.60
12th October 2020Sanj K Patel150,700Open or private sale$21.02$3,167,714.00
9th October 2020Sanj K Patel670Open or private sale$21.00$14,070.00
9th October 2020Sanj K Patel872Exercise of derivative$1.59$1,386.48
9th October 2020Sanj K Patel872Open or private sale$21.00$18,312.00
1st October 2020Bros. Advisors Lp Baker223Grant/award etc.$0.00
1st October 2020Bros. Advisors Lp Baker223Grant/award etc.$0.00
30th September 2020Bros. Advisors Lp Baker317Grant/award etc.$0.00
30th September 2020Bros. Advisors Lp Baker317Grant/award etc.$0.00
Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals Ltd. logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.


Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company. Its products include Rilonacept, Mavrilimumab and KPL-716. The company was founded in July 2015 and is headquartered in Hamilton, Bermuda.


Ticker: KNSA
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1730430
Employees: 111
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $123 M (163%)
Assets, Current: $264 M (9%)
Property, Plant and Equipment, Net: $5 M (0%)
Assets: $271 M (6%)
Accounts Payable, Current: $2 M (-58%)
Accrued Liabilities, Current: $16 M (0%)
Liabilities, Current: $21 M (-26%)
Other Liabilities, Noncurrent: $334 Th (2%)
Liabilities: $21 M (-27%)
Retained Earnings (Accumulated Deficit): $420 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $9 Th (-72%)
Stockholders' Equity (Parent): $250 M (0%)
Liabilities and Equity: $271 M (6%)
Research and Development: $22 M (-48%)
General and Administrative Expenses: $10 M (-47%)
Operating Income/Loss: $32 M (-47%)
Provision for income taxes: $6 M (0%)